Initial Statement of Beneficial Ownership (3)
05 10월 2019 - 1:55AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Zhang Junge |
2. Date of Event Requiring Statement (MM/DD/YYYY)
9/27/2019
|
3. Issuer Name and Ticker or Trading Symbol
Ocugen, Inc. [OCGN]
|
(Last)
(First)
(Middle)
C/O OCUGEN, INC. 5 GREAT VALLEY PARKWAY,, SUITE 160 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
MALVERN, PA 19355
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 212863 | I | By Trust |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Warrants (Right to Buy) | 9/27/2019 | 1/10/2025 | Common Stock | 143820 | $2.77 | I | By Trust |
Warrants (Right to Buy) | 9/27/2019 | 6/12/2027 | Common Stock | 1653 | $7.56 | I | By Trust |
Explanation of Responses: |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Zhang Junge C/O OCUGEN, INC. 5 GREAT VALLEY PARKWAY, SUITE 160 MALVERN, PA 19355 | X |
|
|
|
Signatures
|
/s/ Junge Zhang by [Kelly Beck] his attorney-in-fact | | 10/2/2019 |
**Signature of Reporting Person | Date |
Histogenics (NASDAQ:HSGX)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Histogenics (NASDAQ:HSGX)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
Histogenics Corporation (나스닥)의 실시간 뉴스: 최근 기사 0
More Ocugen, Inc. News Articles